West Nile virus

• 

  Subject Areas on Research

  • An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. 
  • Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. 
  • Correlation of West Nile Virus Incidence in Donated Blood with West Nile Neuroinvasive Disease Rates, United States, 2010-2012. 
  • Delivery of small molecule mast cell activators for West Nile Virus vaccination using acetalated dextran microparticles. 
  • Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. 
  • Identification of microRNAs expressed in two mosquito vectors, Aedes albopictus and Culex quinquefasciatus. 
  • Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. 
  • Nasal Immunization With Small Molecule Mast Cell Activators Enhance Immunity to Co-Administered Subunit Immunogens. 
  • Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus. 
  • Survey of Aedes triseriatus (Diptera: Culicidae) for Lacrosse encephalitis virus and West Nile virus in Lorain County, Ohio. 
  • West Nile virus among hospitalized, febrile patients: a case for expanding diagnostic testing. 
  • West Nile virus in Mexico: evidence of widespread circulation since July 2002. 
  • West Nile virus infection in blood donors in the New York City area during the 2010 seasonal epidemic. 
  • West Nile virus-associated encephalitis in recipients of renal and pancreas transplants: case series and literature review. 
  • Zika virus-related neurotropic flaviviruses infect human placental explants and cause fetal demise in mice.